RPS6KA3 and neoplasm: Like Matriptase, activation of RSK2 is associated with tumour progression, promoting invasiveness and metastasis of glioblastomas and head and neck squamous cell carcinomas (Kang et al., 2010; Sulzmaier et al., 2016).